Katia Roque

Dr. Katia Roque

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2019 in Lung
Verified
Journal Article
Closed access
PDF file
MGMarco Galvez-Nino
Marco Galvez-Nino
RRRossana Ruiz
Rossana Ruiz
JPJoseph Pinto
Joseph Pinto
KRKatia Roque
Katia Roque
RMRaul Mantilla
Raul Mantilla
LMLuis Mas
Luis Mas

13 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
KRKatia Roque
Katia Roque
RRRossana Ruiz
Rossana Ruiz
LMLuis Mas
Luis Mas
DPDaniel Pozza
Daniel Pozza
MVMarina Vancini
Marina Vancini
Ramon Andrade Bezerra De MelloRamon Andrade Bezerra De Mello
Ramon Andrade Bezerra De Mello
The introduction of immunotherapy has brought about a paradigm shift in the management of advanced non-small cell lung cancer (NSCLC). It has not only significantly improved the prognosis of patients but has also become a cornerstone of treatment, particularly in those without oncogenic driver mutations. Immune checkpoint inhibitors (ICIs) play a crucial role in the treatment of lung cancer and can be classified into two main groups: Anti-cytotoxic T lymphocyte antigen-4 (Anti-CTLA-4) and anti-T-cell receptor programmed cell death-1 or its ligand (Anti-PD-1 and Anti-PD-L1). Certainly, the landscape of approved first line immunotherapeutic approaches has expanded to encompass monotherapy, immunotherapy-exclusive protocols, and combinations with chemotherapy. The complexity of decision-making in this realm arises due to the absence of direct prospective comparisons. However, a thorough analysis of the long-term efficacy and safety data derived from pivotal clinical trials can offer valuable insights into optimizing treatment for different patient subsets. Moreover, ongoing research is investigating emerging biomarkers and innovative therapeutic strategies that could potentially refine the current treatment approach even further. In this comprehensive review, our aim is to highlight the latest advances in immunotherapy for advanced NSCLC, including the mechanisms of action, efficacy, safety profiles, and clinical significance of ICI.

1 October 2022 in Future Oncology
Verified
Journal Article
Closed access
KRKatia Roque
Katia Roque
RRRossana Ruiz
Rossana Ruiz
IOIris Otoya-Fernandez
Iris Otoya-Fernandez
JGJosé Galarreta
José Galarreta
TVTatiana Vidaurre
Tatiana Vidaurre
HGHenry Leonidas Gomez
Henry Leonidas Gomez
Background: The COVID-19 pandemic caused discontinuities in cancer care (CC) in most countries. Here, the authors describe the real-world impacts of implementing a contingency plan employing teleme...

19 July 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
KRKatia Roque
Katia Roque
RRRossana Ruiz
Rossana Ruiz
LMLuis Mas
Luis Mas
DPDaniel Pozza
Daniel Pozza
MVMarina Vancini
Marina Vancini
Ramon Andrade Bezerra De MelloRamon Andrade Bezerra De Mello
Ramon Andrade Bezerra De Mello
The advent of immunotherapy has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), improving the prognosis of this disease and becoming a key part of the treatment, especially in the population without an oncogenic driver mutation. Two different groups of immune checkpoint inhibitors (ICIs) are used in lung cancer: Anti- Cytotoxic T-lymphocyte antigen-4 (Anti-CTLA 4) and Anti- T-cell receptor programmed cell death-1 or its ligand (Anti-PD-1 and Anti PD-L1). Here in, we review an uptodate on the use of immunotherapy for advanced NSCLC.

10 January 2024 in Immunotherapy
Verified
Journal Article
Closed access
Ramon Andrade Bezerra De MelloRamon Andrade Bezerra De Mello
Ramon Andrade Bezerra De Mello
KRKatia Roque
Katia Roque
TVThais Pérez Vazquez
Thais Pérez Vazquez
Triple-negative breast cancer (TNBC) comprises 15–20% of all breast cancers (BC). Lacking targeted therapy options, TNBC becomes the focal point of clinical investigations aiming not only to identi...

11 November 2022 in Thoracic Cancer
Verified
Journal Article
Open access
MGMarco Galvez-Nino
Marco Galvez-Nino
RRRossana Ruiz
Rossana Ruiz
KRKatia Roque
Katia Roque
OCOfelia Coanqui
Ofelia Coanqui
NVNatalia Valdivieso
Natalia Valdivieso
LMLuis Mas
Luis Mas
Background: Despite the advances in the management of advanced non–small cell lung cancer (NSCLC), the access to genetic profiling and target therapies remains a challenge in Latin America, even in countries with a higher rate of targetable mutations. The aim of this study is to evaluate the clinical outcomes of anti‐epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) treatment in a Peruvian real‐world setting.Methods: This is a retrospective study of recurrent or advanced NSCLC EGFR mutated patients diagnosed and treated with anti‐EGFR TKI at Instituto Nacional de Enfermedades Neoplásicas (INEN) between January 1, 2015 to December 31, 2020. The outcomes were objective response rate (ORR), progression free survival (PFS), and overall survival (OS).Results: We identify 613 stage IV or recurrent NSCLC patients who were tested for EGFR mutations and found a pathogenic mutation in 39.5% of patients. Only 51.2% of them received anti‐EGFR TKI as institutional treatment. ORR was 58%, after median follow‐up of 32 months, the estimated median PFS was 13.9 months (11.1–16.7 months), and the estimated median OS was 21.7 months (18.5–24.9 months). No differences were found in PFS according to line of treatment or brain metastases at diagnosis (p = 0.46 and p = 0.07, respectively), respect to OS there were no differences line of treatment (p = 0.12), significant difference were found in presence of brain metastases (p = 0.006).Conclusion: Our study demonstrates that erlotinib for advanced NSCLC harboring EGFR‐activating mutations is effective even in patients usually excluded from clinical trial, like those previously exposed to one or more lines of chemotherapy or with brain metastases.